TrialCancer medicine2018

Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosis.

Stine Ulrik Mikkelsen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.